Belite Bio, Inc
NASDAQ:BLTEBiotechnology
+$0.46 today
- Market cap
- $6.29B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
Volume 0.09M
Average 0.17M
BLTE Common Stock Issued
Cash raised by issuing new shares.
Belite Bio, IncNASDAQ: BLTE
Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026
Common stock issued outflow grows to $0
Q2 FY2026 common stock issued was $0, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $132.99K. Over 3 fiscal years it compounded at +97.5% a year.
Context
- Common stock issued increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock issued holds near $0 or moves back toward the trailing-twelve-month quarterly average of $33.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 292.86M USD
- Year-over-year change
- +593.4%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 292.86M | +593.4% |
| FY2024 | 2024-12-31 | 42.24M | -45.3% |
| FY2023 | 2023-12-31 | 77.19M | +103.2% |
| FY2022 | 2022-12-31 | 37.99M | +6616.3% |
| FY2021 | 2021-12-31 | (583K) | — |
Common Stock Issued vs competitors
How BLTE compares with its peers on the latest reported figures
- BLTE's LTM Jun 2026 common stock issued of $132.99K is the smallest of the 6 companies compared; the peer median is $56.66M.
- Over three fiscal years its annual growth of +97.5% compares with a peer median of +237.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $187.21M | +12713.7% | +351.0% | — | |
| LTM Mar 2026 | $175.68M | +6.6% | +662.5% | 2307.0% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $56.66M | +577.7% | +123.1% | 472.9% |
| LTM Mar 2026 | $56M | +49.1% | -32.5% | 1254.3% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $50.07M | — | — | — |
BLTEBelite Bio, Inc | LTM Jun 2026 | $132.99K | — | +97.5% | — |
| Peer median (excluding BLTE) | $56.66M | +313.4% | +237.0% | 1254.3% | |
Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| Deferred Income Tax | 0 | (1.91M) | (4.69M) | 0 | 0 |
| Stock-Based Compensation | 1.53M | 1.48M | 3.82M | 8.99M | 38.92M |
| Change in Working Capital | 640K | (491K) | (2.43M) | 1.13M | 2.55M |
| Accounts Receivables | 0 | (32K) | (72K) | 74K | (66K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 640K | (459K) | (2.36M) | 1.06M | 2.62M |
| Other Non-Cash Items | (8K) | 1.91M | 4.69M | (3.66M) | (1.31M) |
| Operating Cash Flow | (7.47M) | (11.46M) | (29.84M) | (29.23M) | (36.99M) |
| Capital Expenditures | (74K) | (394K) | (63K) | (151K) | (178K) |
| Acquisitions (Net) | 18K | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (188.27M) | (451.99M) |
| Sales of Investments | 0 | 0 | 0 | 77.84M | 147.07M |
| Other Investing Activities | 0 | 0 | 0 | (35K) | 0 |
| Investing Cash Flow | (56K) | (394K) | (63K) | (110.57M) | (305.11M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (583K) | 37.99M | 77.19M | 42.24M | 292.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.03M) | (1.23M) | 41.36M | 370.37M |
| Financing Cash Flow | (583K) | 36.96M | 75.96M | 83.6M | 663.23M |
| Effect of Forex Changes | (161K) | (366K) | 9K | (269K) | 117K |
| Net Change in Cash | (8.27M) | 24.75M | 46.07M | (56.48M) | 321.26M |
| Free Cash Flow | (7.55M) | (11.85M) | (29.9M) | (29.39M) | (37.17M) |
Belite Bio, Inc
NASDAQ:BLTE
Intrinsic Alpha fair value
Locked
Current Price
$156.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.